Cargando…
Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy
SIMPLE SUMMARY: Gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) are a family of rare cancers with rising incidence in recent years. GEP NEN tumor cells are difficult to propagate, and few cellular and patient-derived xenograft (PDX) models are available for testing new therapies and study...
Autores principales: | Tran, Catherine G., Borbon, Luis C., Mudd, Jacqueline L., Abusada, Ellen, AghaAmiri, Solmaz, Ghosh, Sukhen C., Vargas, Servando Hernandez, Li, Guiying, Beyer, Gabriella V., McDonough, Mary, Li, Rachel, Chan, Carlos H.F., Walsh, Susan A., Wadas, Thaddeus J., O’Dorisio, Thomas, O’Dorisio, M Sue, Govindan, Ramaswamy, Cliften, Paul F., Azhdarinia, Ali, Bellizzi, Andrew M., Fields, Ryan C., Howe, James R., Ear, Po Hien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033026/ https://www.ncbi.nlm.nih.gov/pubmed/35454817 http://dx.doi.org/10.3390/cancers14081910 |
Ejemplares similares
-
SUN-LB26 Radioligand Theranostics of Endocrine-Related Cancers; A New, Revolutionary Approach
por: Harris, Alan G, et al.
Publicado: (2020) -
Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues
por: Anthony, Lowell B., et al.
Publicado: (2021) -
Growing vascular endothelial cells express somatostatin subtype 2 receptors
por: Watson, J C, et al.
Publicado: (2001) -
Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021) -
Prospective Analysis of the Impact of (68)Ga-DOTATOC Positron Emission Tomography–Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors
por: Ghobrial, Silvia N., et al.
Publicado: (2020)